Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
|Tested species reactivity||Human|
|Published species reactivity||Human|
|Host / Isotype||Mouse / IgG2a|
|Immunogen||Full length recombinant p21protien.|
|Contains||0.08% sodium azide|
|Storage Conditions||-20° C, Avoid Freeze/Thaw Cycles|
|Tested Applications||Dilution *|
|Immunohistochemistry (IHC)||Assay Dependent|
|Immunoprecipitation (IP)||Assay Dependent|
|Western Blot (WB)||Assay Dependent|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
This gene encodes a potent cyclin-dependent kinase inhibitor. The encoded protein binds to and inhibits the activity of cyclin-CDK2 or -CDK4 complexes, and thus functions as a regulator of cell cycle progression at G1. The expression of this gene is tightly controlled by the tumor suppressor protein p53, through which this protein mediates the p53-dependent cell cycle G1 phase arrest in response to a variety of stress stimuli. This protein can interact with proliferating cell nuclear antigen (PCNA), a DNA polymerase accessory factor, and plays a regulatory role in S phase DNA replication and DNA damage repair. This protein was reported to be specifically cleaved by CASP3-like caspases, which thus leads to a dramatic activation of CDK2, and may be instrumental in the execution of apoptosis following caspase activation. Multiple alternatively spliced variants have been found for this gene.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
CDK4 T172 phosphorylation is central in a CDK7-dependent bidirectional CDK4/CDK2 interplay mediated by p21 phosphorylation at the restriction point.
MA1-12303 was used in western blot to study the roles CDK7 and p21 in regulating the T172 phosphorylation of CDK4 at the restriction point
|Bisteau X,Paternot S,Colleoni B,Ecker K,Coulonval K,De Groote P,Declercq W,Hengst L,Roger PP||PLoS genetics (9:null)||2013|
Evaluation of immunohistochemical expression of p53, p21, p27, cyclin D1, and Ki67 in oral and oropharyngeal squamous cell carcinoma.
MA1-12303 was used in immunohistochemistry to study the immunohistochemical expression of p53, p21, p27, cyclin D1 and Ki67 in oral and oropharyngeal squamous cell carcinoma
|Perisanidis C,Perisanidis B,Wrba F,Brandstetter A,El Gazzar S,Papadogeorgakis N,Seemann R,Ewers R,Kyzas PA,Filipits M||Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology (41:40)||2012|
Cell cycle regulators show diagnostic and prognostic utility for differentiated thyroid cancer.
MA1-12303 was used in immunohistochemistry to study the diagnostic and prognostic value of cell cycle regulators in differentiated thyroid cancer
|Melck A,Masoudi H,Griffith OL,Rajput A,Wilkins G,Bugis S,Jones SJ,Wiseman SM||Annals of surgical oncology (14:3403)||2007|
p21CDKN1A participates in base excision repair by regulating the activity of poly(ADP-ribose) polymerase-1.
MA1-12303 was used in immunocytochemistry to study the role of poly(ADP-ribose) polymerase-1 in the mechanism by which p21CDKN1A participates in base excision repair
|Cazzalini O,Donà F,Savio M,Tillhon M,Maccario C,Perucca P,Stivala LA,Scovassi AI,Prosperi E||DNA repair (9:627)||2010|
CAP20; CDK-interacting protein 1; CDK-interaction protein 1; CDKN1; CDNK1A; cyclin-dependent kinase inhibitor 1; cyclin-dependent kinase inhibitor 1A (p21, Cip1); DNA synthesis inhibitor; MDA-6; melanoma differentiation associated protein 6; p21CIP1; SDI1; WAF1; wild-type p53-activated fragment 1
CAP20; CDKN1; CDKN1A; CIP1; MDA-6; MDA6; P21; p21CIP1; PIC1; SDI1; WAF1